Divi's Laboratories reported Q2 FY27 net profit of ₹2,997 Cr on revenue of ₹38,954 Cr, with profit up +0.1% year-on-year and ahead of street estimates. The stock rose sharply in reaction as investors weighed the margin trend and management's outlook for the rest of the year.
Last 8 quarters / 3 years
| Period | Revenue | Net Profit | EPS | YoY | QoQ |
|---|---|---|---|---|---|
| Q3 FY25 | ₹33,908 Cr | ₹2,412 Cr | ₹90.65 | — | — |
| Q4 FY25 | ₹33,260 Cr | ₹2,917 Cr | ₹109.62 | — | +20.9% |
| Q1 FY26 | ₹34,273 Cr | ₹2,701 Cr | ₹101.48 | — | -7.4% |
| Q2 FY26 | ₹34,264 Cr | ₹2,994 Cr | ₹112.53 | — | +10.9% |
| Q3 FY26 | ₹36,305 Cr | ₹3,439 Cr | ₹129.25 | +42.6% | +14.9% |
| Q4 FY26 | ₹36,962 Cr | ₹2,859 Cr | ₹107.43 | -2.0% | -16.9% |
| Q1 FY27 | ₹38,683 Cr | ₹3,673 Cr | ₹138.04 | +36.0% | +28.5% |
| Q2 FY27 | ₹38,954 Cr | ₹2,997 Cr | ₹112.64 | +0.1% | -18.4% |
Last 4 quarters
Recent large transactions
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 27 Aug 2026 | Graviton Research Capital | SELL | 6,97,832 | ₹5,843.47 |
Divi's Laboratories reported revenue and profit broadly in line with Street expectations, with management flagging stable demand and a healthy order pipeline into the second half.
Divi's Laboratories entered a strategic partnership to widen its addressable market. Management expects the tie-up to contribute modestly to revenue over the next few quarters.
In an exchange filing, Divi's Laboratories said its board cleared a multi-year investment to expand capacity, aimed at meeting demand and improving operating leverage over the medium term.
Several brokerages maintained a positive stance on Divi's Laboratories, citing improving return ratios and a clearer growth runway, while a few flagged valuations as the key risk.
Tap a metric label to learn what it means.
Pharmaceuticals
| Company | P/E | 1Y |
|---|---|---|
| Sun Pharmaceutical ₹4,27,000 Cr | 48.5 | +36.2% |
| Cipla ₹1,23,000 Cr | 47.7 | +6.9% |
| Dr. Reddy's Laboratories ₹1,07,000 Cr | 50.3 | +6.6% |
| Apollo Hospitals ₹99,000 Cr | 40.8 | +25.2% |
Divi's Laboratories is a leading Indian company in the pharmaceuticals space within the Healthcare sector. It is a constituent of the Nifty 50 and is actively tracked by institutional and retail investors.